Printer Friendly

Browse Metastasis topic

Drug therapy subtopic

 

Articles

1-300 out of 413 article(s) nextnext page
Title Author Type Date Words
Preclinical Data Show Agilvax AX09 Immunotherapy Reduces Tumor Growth and Pulmonary Metastases in Triple Negative Breast Cancer. Dec 7, 2017 252
Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients. Oct 16, 2017 900
Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer. Clinical report Oct 16, 2017 665
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer. Oct 12, 2017 3098
OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse IL-12 in Combination with Merck's KEYTRUDA (pembrolizumab). Oct 10, 2017 1321
Radiation-immunotherapy combination can slow tumor growth for some patients with metastatic late-stage cancer. Sep 24, 2017 1894
United States : Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer. Sep 16, 2017 355
United States : FDA Approves Amgen And Allergan's MVASI (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer. Sep 15, 2017 390
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer. Sep 14, 2017 2828
Israel : Life-Prolonging Treatment for Metastatic Non-Small Cell Lung Cancer Approved for Clinical Trials. Sep 1, 2017 422
Switzerland : Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor. Aug 28, 2017 358
Madison Vaccines Doses First Patient in Trial of MVI-816 Plus Keytruda for Metastatic, Treatment-Resistant Prostate Cancer. Aug 4, 2017 308
New drug 'cuts cancer tumours by up to half'. Aug 3, 2017 170
United States : Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan. Aug 2, 2017 475
Radiation therapy--an effective tool for analgesia in metastatic bone disease in breast cancer. Negi, Preety; Kingsley, Pamela Alice; Sachdeva, Jaineet; Srivastava, Himanshu Report Jul 31, 2017 2888
Neon Therapeutics, Apexigen to Collaborate in Clinical Trial for Metastatic Melanoma Treatment. Jul 26, 2017 289
US FDA Approves Bristol-Myers Squibb's Yervoy for Treatment of Adolescents with Unresectable or Metastatic Melanoma. Jul 25, 2017 470
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer. Jul 10, 2017 1565
Future Cancer Treatment Could Stop Disease From Spreading. Jul 3, 2017 574
Comparative effect of Maitake Pro4x with Chemotherapy breast cancer treatment. Braico, Diego Aguilera; Roldan-Deamicis, Agustina; Brie, Belen; Balogh, Gabriela Andrea Report Jul 1, 2017 5426
Effectiveness and safety of percutaneous vertebroplasty in the treatment of spinal metastatic tumor. Jun 30, 2017 3036
FDA Approves Vectibix (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer. Jun 29, 2017 3751
OncoSec wins US FDA's orphan drug designation for tavokinogene telsaplasmid to treat unresectable metastatic melanoma. Jun 9, 2017 253
OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma. Jun 8, 2017 661
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer. Jun 5, 2017 1946
United States : First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases. Jun 5, 2017 557
Array BioPharma, Bristol-Myers Squibb Partner to Study Treatment Regimen for Metastatic Colorectal Cancer. Jun 5, 2017 355
Immunotherapy Drug Effective For Metastatic Triple Negative Breast Cancer. Jun 3, 2017 781
ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors. Jun 3, 2017 1591
Novartis wins US FDA approval to expand use of Zykadia for treating patients with metastatic non-small cell lung cancer. May 29, 2017 278
Novartis wins US FDA approval to expand use of Zykadia for treating patients with metastatic non-small cell lung cancer. May 29, 2017 274
Switzerland : Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC). May 29, 2017 440
Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC). May 26, 2017 2928
United States : FDA approves first cancer treatment for any solid tumor with a specific genetic feature. May 24, 2017 835
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer to be Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. May 23, 2017 1562
Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment. Clinical report May 23, 2017 950
FDA approves first cancer treatment for any solid tumor with a specific genetic feature. May 23, 2017 971
Pfizer Inc announces US FDA approval of BAVENCIO (avelumab) for Advanced Bladder Cancer; Its second approval in less than two months. May 10, 2017 285
Pfizer Inc announces US FDA approval of BAVENCIO (avelumab) for Advanced Bladder Cancer; Its second approval in less than two months. May 10, 2017 281
FDA Approves US Merck's Keytruda as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression. May 10, 2017 390
United States : FDA Grants BAVENCIO (avelumab) Approval for a Common Type of Advanced Bladder Cancer. May 10, 2017 666
FDA Grants BAVENCIO (avelumab) Approval for a Common Type of Advanced Bladder Cancer. May 9, 2017 4074
Oncolytics Biotech[R] Inc. Announces FDA Fast Track Designation for REOLYSIN[R] in Metastatic Breast Cancer. May 8, 2017 785
Novartis receives FDA approval for first-of-its-kind Kisqali Femara Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer. May 8, 2017 1989
Japan : Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (brigatinib). May 2, 2017 426
FDA approves first treatment for metastatic Merkel cell. Nikolaides, Laura May 1, 2017 341
United States : A Potential Cure for Metastatic Prostate Cancer? Treatment Combination Shows Early Promise. Apr 20, 2017 436
Erytech publishes positive phase 2b data for eryaspase, a treatment for metastatic pancreatic cancer. Mar 27, 2017 292
Erytech publishes positive phase 2b data for eryaspase, a treatment for metastatic pancreatic cancer. Mar 27, 2017 288
Pfizer Inc wins US FDA approval for BAVENCIO (avelumab) to treat metastatic merkel cell carcinoma. Mar 24, 2017 306
Pfizer Inc wins US FDA approval for BAVENCIO (avelumab) to treat metastatic merkel cell carcinoma. Mar 24, 2017 302
Delhi High Court gives Biocon, Mylan green light to sell biosimilar cancer drug. Mar 3, 2017 267
Delhi High Court gives Biocon, Mylan green light to sell biosimilar cancer drug. Mar 3, 2017 263
Bristol-Myers Squibb passes US FDA approval for Opdivo for treating metastatic urothelial carcinoma. Feb 3, 2017 276
Bristol-Myers Squibb passes US FDA approval for Opdivo for treating metastatic urothelial carcinoma. Feb 3, 2017 272
Bayer Submits Supplemental New Drug Application for Stivarga (regorafenib) for Advanced Liver Cancer. Nov 7, 2016 4000
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer. Nov 4, 2016 1190
Genentech, a member of the Roche Group, received approval from the FDA for TECENTRIQ (atezolizumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following chemotherapy, and have progressed on another targeted therapy if their tumor has EGFR or ALK gene abnormalities. Nov 1, 2016 172
amcure announces initiation and first patient treated in a Phase I/Ib clinical study of AMC303 for cancer treatment. Clinical report Oct 27, 2016 314
amcure announces initiation and first patient treated in a Phase I/Ib clinical study of AMC303 for cancer treatment. Clinical report Oct 27, 2016 310
United States : FDA approves genentechs cancer immunotherapy tecentriq(atezolizumab) for people with a specific type of metastatic lung cancer. Oct 19, 2016 382
PharmaEngine Announces Onivyde(R) Receives European Marketing Authorization for the Treatment of Metastatic Adenocarcinoma of the Pancreas Following Gemcitabine based Therapy. Oct 18, 2016 839
Shire Granted EU Marketing Authorization of Onivyde, in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy. Oct 18, 2016 3051
Shire Granted EU Marketing Authorization of Onivyde, in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy. Oct 18, 2016 3056
BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA (pembrolizumab) for Treatment of Pancreatic Cancer. Sep 20, 2016 1360
United States : Oxygen can impair cancer immunotherapy in mice. Aug 26, 2016 488
United States : FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy. Aug 17, 2016 828
United States : FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma wit. Aug 6, 2016 296
Japan : PharmaEngine Announces ONIVYDE? Regimen Receives CHMP Positive Opinion for the Treatment of Metastatic Pancreatic Cancer. Jul 27, 2016 346
Coverage of INSIGHTEC's Exablate for Pain Palliation of Bone Metastases Expands to 99.8 Million Members in the US. Jul 27, 2016 525
PharmaEngine Announces ONIVYDE(R) Regimen Receives CHMP Positive Opinion for the Treatment of Metastatic Pancreatic Cancer. Jul 25, 2016 779
New and Emerging Treatments for Metastatic Brain Tumors Added to Featured Topics at American Brain Tumor Association's Annual Conference. Conference news Jul 12, 2016 885
Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences. Jun 4, 2016 1161
Taiwan Province of China : PharmaEngine Announces Korean Ministry of Food and Drug Safety Accepted the NDA Filing of ONIVYDE for the Treatment of Metastatic Pancreatic Cancer. May 14, 2016 260
PharmaEngine Announces Korean Ministry of Food and Drug Safety Accepted the NDA Filing of ONIVYDE(R) for the Treatment of Metastatic Pancreatic Cancer. May 10, 2016 629
United States : Eisai receives approval for new Indication for Anticancer Agent Halavenfor Treatment of advanced Liposarcoma in Europe. May 7, 2016 495
Supply of Drugs for treatment of metastatic melanoma. Apr 23, 2016 144
Study: Antioxidants in Antidiabetic Drugs May Fuel Cancer Spread. Apr 15, 2016 305
Japan : Eisai receives positive CHMP opinion on new indication for Anticancer Agent Halaven for treatment of advanced Liposarcoma. Apr 6, 2016 576
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma. Apr 5, 2016 1544
Pfizer wins US FDA's approval for sNDA for XALKORI for treating patients with ROS1-positive metastatic NSCLC. Mar 14, 2016 328
Pfizer wins US FDA's approval for sNDA for XALKORI for treating patients with ROS1-positive metastatic NSCLC. Mar 14, 2016 324
FDA Accepts For Review Supplemental New Drug Application for XTANDI (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide. Feb 22, 2016 1822
Drugs for treatment of metastatic melanoma. Feb 15, 2016 134
Some hospitals funded oncology drugs with indications of cancer with metastasis to the bone, prostate cancer that has spread and skin cancer has spread. Jan 13, 2016 117
Eisai Submits New Application in Europe for In-House Developed Anticancer Agent Lenvatinib Seeking Approval for Indication Covering Renal Cell Carcinoma. Jan 12, 2016 1223
Circulating Tumor Cells Linked with Treatment Resistance and Response in Prostate Cancer Patients. Jan 4, 2016 1027
United States : Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-. Dec 9, 2015 395
Eli Lilly and Company wins US FDA's approval for Portrazza for first-line treatment of metastatic squamous non-small cell lung cancer. Nov 25, 2015 284
Eli Lilly and Company wins US FDA's approval for Portrazza for first-line treatment of metastatic squamous non-small cell lung cancer. Nov 25, 2015 280
Memgen Announces Preclinical Results for Its ISF35 Cancer Immunotherapy with Checkpoint Inhibitors in Metastatic Melanoma. Financial report Nov 18, 2015 540
United States : TAGRISSO (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Nov 14, 2015 597
TAGRISSO(TM) (osimertinib) (AZD9291) Approved By The US FDA As Treatment For Patients With EGFR T790M Mutation-Positive Metastatic Non-Small Cell Lung Cancer. Nov 13, 2015 1679
Bristol-Myers Squibb Co. received approval from the FDA for Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Nov 1, 2015 185
United States : U.S. FDA Approves YONDELIS (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma. Oct 24, 2015 353
U.S. FDA Approves YONDELIS (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma. Oct 23, 2015 2854
PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer. Oct 22, 2015 2311
FDA Approves Post-Gemcitabine Therapy For Patients With Metastatic Pancreatic Cancer. Oct 22, 2015 647
Germany : Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma. Oct 8, 2015 394
Quest Diagnostics Introduces Dako's PD-L1 Companion Diagnostic for KEYTRUDA, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy. Oct 2, 2015 940
Docetaxel extends survival in metastatic prostate ca. Nelson, Roxanne Sep 15, 2015 690
Metastatic renal cell cancer: summary from ASCO 2015. Conference notes Aug 1, 2015 2447
Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer. Apr 27, 2015 1155
Life Extending Metastatic Breast Cancer Treatment Halaven (Eribulin) Launches in the United Arab Emirates. Apr 21, 2015 1034
INSIGHTEC Announces BCBS North Carolina and Horizon BCBS of New Jersey Published Positive Coverage of MRgFUS Treatments for Pain Palliation of Bone Cancer Metastases. Apr 16, 2015 741
Taiho Submits TAS-102 Marketing Authorisation Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer. Mar 2, 2015 1161
Taiho Submits TAS-102 Marketing Authorisation Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer. Mar 2, 2015 1189
Taiho Oncology, Inc. Announces TAS-102 New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA. Feb 23, 2015 1151
FDA Approves Eisai's LENVIMA(TM) (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Feb 13, 2015 2610
Multimedia Assets Now Available: FDA Approves Eisai's LENVIMA(TM) (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Feb 13, 2015 2642
Bristol-Myers Squibb wins US FDA approval for Opdivo (nivolumab) for treating metastatic melanoma. Dec 23, 2014 119
Bristol-Myers Squibb wins US FDA approval for Opdivo (nivolumab) for treating metastatic melanoma. Dec 23, 2014 115
Taiho Oncology Completes Submission of TAS-102 New Drug Application to the US Food and Drug Administration for the Treatment of Refractory Metastatic Colorectal Cancer. Dec 22, 2014 1056
OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer. Financial report Dec 19, 2014 1538
Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: a diagnostic pitfall. Yigit, Nuri; Geyer, Julia Turbiner Case study Dec 1, 2014 1849
Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer. Oct 31, 2014 2207
Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer. Oct 20, 2014 1091
Multiple metastases from ovarian cancer. Singh, D.; Kapoor, A.; Jakhar, S.L.; Bagri, P.K.; Kumar, H.S. Report Oct 1, 2014 1455
Life-extending Metastatic Breast Cancer Treatment Halaven (Eribulin) Launches in Australia. Sep 30, 2014 1664
XTANDI (enzalutamide) receives expanded approval from FDA for treatment of metastatic castration-resistant prostate cancer. Sep 30, 2014 473
Germany : Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer. Sep 17, 2014 438
Merck wins accelerated approval from the US FDA for KEYTRUDA for unresectable or metastatic melanoma. Sep 5, 2014 235
Merck wins accelerated approval from the US FDA for KEYTRUDA for unresectable or metastatic melanoma. Sep 5, 2014 231
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation. Sep 3, 2014 714
First ever treatment to prevent tumor metastasis revealed. Jul 25, 2014 127
Life-Extending Treatment for Metastatic Breast Cancer Now Licenced After One Prior Chemotherapy. Jul 3, 2014 2154
LUNGevity Foundation Applauds FDA Approval of Zykadia(TM) (ceritinib) as Additional Tool in Arsenal for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. May 1, 2014 637
OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer. Apr 23, 2014 865
Halaven (Eribulin) Now Commercially Available in Lebanon for the Treatment of Metastatic Breast Cancer. Apr 6, 2014 1384
Bayer Initiates Phase 3 Trial of Xofigo (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer. Apr 2, 2014 1838
Y-90 Provides New, Safe Treatment for Metastatic Breast Cancer. Mar 24, 2014 983
Specialised Therapeutics Australia Receives Therapeutic Goods Administration Approval for Abraxane(R) in Combination with Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer. Mar 18, 2014 2028
Canadian content at GU-ASCO 2014: Highlights of research involving Canadian researchers. Kapoor, Anil Conference notes Mar 1, 2014 2105
Innovative Metastatic Breast Cancer Treatment Halaven (Eribulin) Recieves Reimbursement Approval in the Czech Republic. Jan 5, 2014 1587
Life-extending Metastatic Breast Cancer Treatment Now Available in the Republic of Ireland. Jan 5, 2014 2017
Pfizer Inc wins US FDA's regular approval for XALKORI for patients with metastatic ALK-positive non-small cell lung cancer. Nov 22, 2013 235
Pfizer Inc wins US FDA's regular approval for XALKORI for patients with metastatic ALK-positive non-small cell lung cancer. Nov 22, 2013 231
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment. Nov 22, 2013 3531
New Treatment Offers Hope to Advanced Prostate Cancer Patients. Oct 17, 2013 734
Innovative Metastatic Breast Cancer Treatment Halaven (eribulin) is Available in Belgium. Sep 30, 2013 1936
Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013. Sep 28, 2013 404
Germany : Bayer Receives Recommendation for Approval of Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases in the European Union. Sep 21, 2013 443
United Kingdom : GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma. Sep 17, 2013 259
US FDA grants Priority Review to SmithKline for dabrafenib/trametinib combination in metastatic melanoma. Sep 16, 2013 178
US FDA grants Priority Review to SmithKline for dabrafenib/trametinib combination in metastatic melanoma. Sep 16, 2013 174
Halaven (eribulin), the First and Only Single-agent Treatment to Extend Survival in Later Stage Metastatic Breast Cancer, Launches in Russia. Sep 11, 2013 1594
United Kingdom : GSK receives marketing authorisation from the European Commission for Tafinlar (dabrafenib), an oral treatment for unresectable or metastatic melanoma in adult patients with a BRAF V. Sep 3, 2013 371
Novel Life-Extending Metastatic Breast Cancer Treatment Now Available in Spain. Sep 3, 2013 1916
Mucinous breast cancer with solitary metastasis to humeral head: a case report. Alajmi, Adil Aljarrah; Hashmi, Maryam Al-; Malik, Kamran Ahmad; Sukhpal, Sawhney; Hussein, Samir; Ri Clinical report Sep 1, 2013 1789
ExAblate Receives Approval of Health Canada for the Treatment of Uterine Fibroids and Pain Palliation of Bone Metastases. Aug 22, 2013 401
ExAblate Receives Approval of Health Canada for the Treatment of Uterine Fibroids and Pain Palliation of Bone Metastases. Aug 22, 2013 406
Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer. Jul 9, 2013 756
Germany,United States : Bayer s Regorafenib Recommended for Approval in the European Union for the Treatment of Metastatic Colorectal Cancer. Jun 29, 2013 349
Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting. Jun 1, 2013 2014
Eisai Files for Earlier use of Halaven (Eribulin) for the Treatment of Metastatic Breast Cancer. May 6, 2013 1366
Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report. Morita, Jun; Naoe, Michio; Ogawa, Yu; Nakasato, Takehiko; Sugahara, Motoko; Morita, Masashi; Fuji, K Clinical report May 1, 2013 2385
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer. Apr 2, 2013 1315
Bayer's Stivarga (regorafenib) Tablets Approved in Japan. Mar 25, 2013 2013
European Study Concludes Kiva Effective in Treating Severe Pain From Vertebral Metastases. Mar 18, 2013 1001
Canada : Bayer s Stivarga (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST. Feb 26, 2013 269
Possible drug target to stop breast cancer metastasis identified. Jan 28, 2013 371
Exelixis Inc unveils US FDA approved COMETRIQ in the US for metastatic medullary thyroid cancer. Jan 25, 2013 156
Exelixis Inc unveils US FDA approved COMETRIQ in the US for metastatic medullary thyroid cancer. Jan 25, 2013 152
Switzerland : FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer. Jan 24, 2013 390
Large U.S. Multi-Center Study Supports the Safety and Efficacy of Sirtex's SIR-Spheres[R] microspheres in Treating Colorectal Liver Metastases. Jan 24, 2013 1057
Bayer Submits New Drug Application for Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. Dec 14, 2012 1068
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer. Dec 11, 2012 755
Debiopharm Group unveils Pamorelin LA in India for the treatment of prostate cancer. Dec 10, 2012 194
Debiopharm Group unveils Pamorelin LA in India for the treatment of prostate cancer. Dec 10, 2012 190
Ginsenoside: novel agent for breast cancer? Dec 1, 2012 549
FDA Approves COMETRIQ[TM] (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid Cancer. Nov 29, 2012 1572
Astellas Submits Supplemental New Drug Application to FDA for Tarceva as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer. Nov 20, 2012 1026
OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients. Nov 15, 2012 1421
Clovis Oncology reports disappointing results from testing of pancreatic cancer drug. Nov 12, 2012 200
Clovis Oncology reports disappointing results from testing of pancreatic cancer drug. Nov 12, 2012 196
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer. Nov 7, 2012 1896
Germany : Bayer s Stivarga(regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors. Oct 30, 2012 450
Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome. Oct 12, 2012 1423
Lexicon Initiates Phase 3 Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome. Oct 12, 2012 920
LUNGevity Foundation Applauds FDA Approval of Abraxane as Additional Tool in Arsenal for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Oct 12, 2012 622
BioAlliance Pharma SA: Presentation of Phase I clinical results with AMEP[R] biotherapy in the treatment of metastatic melanoma. Oct 1, 2012 867
Low-dose Thalidomide in patients with Metastatic Renal Cell Carcinoma. Tunio, Mutahir Ali; Hashmi, Altaf; Qayyum, Rehan Masood Abdul; Naimatullah, Najeeb Report Sep 30, 2012 2783
Canada : Bayer s Stivarga (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer. Sep 28, 2012 296
Germany : Bayer s Stivarga (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer. Sep 28, 2012 356
United States : FDA approves new treatment for advanced colorectal cancer. Sep 28, 2012 443
Bayer's Stivarga (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer. Sep 27, 2012 2630
Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease. Company overview Sep 24, 2012 1132
Australia : Eisai receives approval to market anticancer agent halaven in Australia. Sep 8, 2012 292
Eisai Receives Approval to Market Anticancer Agent Halaven(R) in Australia. Sep 7, 2012 1138
Japan : Eisai receives approval for anticancer agent halaven in South Korea. Sep 4, 2012 297
Medivation Inc & Astellas Pharma Inc receives US FDA's approval for XTANDI for patients with metastatic castration-resistant prostate cancer. Sep 3, 2012 168
Medivation Inc & Astellas Pharma Inc receives US FDA's approval for XTANDI for patients with metastatic castration-resistant prostate cancer. Sep 3, 2012 164
United States : FDA approves new treatment for a type of late stage prostate cancer. Sep 1, 2012 452
Germany : Bayer s Regorafenib Submitted for U.S. Marketing Authorization for the Treatment of Gastrointestinal Stromal Tumors (GIST). Aug 31, 2012 391
Delcath Systems Inc files NDA with US FDA for proprietary chemosaturation system to treat patients with unresectable metastatic melanoma in the liver. Aug 16, 2012 168
Delcath Systems Inc files NDA with US FDA for proprietary chemosaturation system to treat patients with unresectable metastatic melanoma in the liver. Aug 16, 2012 164
Qiagen Diagnostic Approved for Colorectal Cancer*. Aug 1, 2012 1081
Lab21 among First to Offer FDA Approved Companion Diagnostic in the US. Jul 12, 2012 484
New Breast Cancer Treatment Available in France. Jul 9, 2012 1489
Bristol-Meyers Squibb and Eli Lilly announce FDA approval of ERBITUX. Jul 9, 2012 254
U.S. FDA Grants Priority Review to the New Drug Application for Bayer's Regorafenib to Treat Patients with Metastatic Colorectal Cancer. Jun 28, 2012 920
New candidate drug stops cancer metastasis and regenerates nerve cells. Jun 22, 2012 721
Tokai Pharmaceuticals' Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer. Jun 12, 2012 745
FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer. Jun 9, 2012 2330
HIV drug `may slow down metastatic breast cancer`. Jun 7, 2012 557
Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting. Jun 4, 2012 2042
Large U.S. Multi-Center Study Confirms Safety and Efficacy of SIR-Spheres[R] microspheres in More Than 600 Patients with Unresectable Liver Metastases. Clinical report Jun 4, 2012 975
Intermittent therapy inferior to hormone therapy for prostrate cancer. Jun 4, 2012 801
New Drug Slows Advanced Prostate Cancer. Clinical report Jun 4, 2012 781
Genentech's Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III Trial. Jun 3, 2012 1494
Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer. May 30, 2012 851
Bayer Submits New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer. May 23, 2012 1130
New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer. May 23, 2012 1263
In 2020, FOLFIRI Plus Ramucirumab Will Earn Decision Resources' Proprietary Clinical Gold-Standard Status for the Second-Line Treatment of Metastatic Colorectal Cancer. May 8, 2012 770
FDA grants review for cancer drug from Sanofi. Apr 5, 2012 123
Docetaxel Dominates First-Line Metastatic Castrate-Resistant Prostate Cancer Treatment, But Total Patient Share of Zytiga and Jevtana Reach Nearly 50 Percent in the Second and Third-Line Settings According to Surveyed Physicians. Clinical report Apr 3, 2012 732
Beta - blockers may help with breast cancer treatment: may help prevent heart failure and death from metastatic disease. Apr 1, 2012 468
Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours. Beausoleil, Michel; Ernst, D. Scott; Stitt, Larry; Winquist, Eric Report Apr 1, 2012 3536
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer. Mar 5, 2012 1670
New melanoma drug may accelerate secondary skin cancers. Mar 1, 2012 164
Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer. Feb 13, 2012 746
Researchers take a new look at ovarian cancer treatment. Jan 18, 2012 399
Drug Improves Survival of Colorectal Cancer Patients, Trial Results Show. Jan 17, 2012 472
Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development. Jan 3, 2012 5150
Targeted therapies in breast cancer: tailoring treatment to the molecular drivers of disease progression. Hicks, David G. Report Jan 1, 2012 1911
Avastin approval for breast cancer treatment revoked by FDA. Jan 1, 2012 137
NICE says no to AstraZeneca's breast cancer drug Faslodex. Dec 15, 2011 163
Health Canada approves Eisai's anticancer agent Halaven. Dec 15, 2011 161
Eisai Announces Canadian Approval of its Anticancer Agent Halaven. Dec 15, 2011 494
Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma. Dec 8, 2011 1149
Chemotherapy to the liver delays progression of metastatic melanoma. McBride, Deborah Brief article Dec 1, 2011 264
FDA revokes Avastin approval for breast cancer. Mechcatie, Elizabeth Dec 1, 2011 615
Susan G. Komen for the Cure[R] Statement on U.S. Food and Drug Administration's Decision Removing Avastin from Approved Breast Cancer Drugs. Nov 18, 2011 392
Women With Advanced Breast Cancer Denied Life-extending Treatment Halaven(R) (black triangle drug) (Eribulin). Nov 16, 2011 1990
Vectibix (Panitumumab) Granted Approval for Expanded Indications in the European Union. Nov 15, 2011 2553
Medical Oncologists Have Rapidly Adopted Yervoy and Zelboraf in All Lines of Therapy for the Treatment of Metastatic Melanoma. Nov 14, 2011 785
Erbitux (cetuximab) gets FDA approval for metastatic head and neck cancer. Nov 8, 2011 351
FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer. Nov 7, 2011 729
Pancreatic Cancer Drug Pioneered by NantWorks Chairman Patrick Soon-Shiong Shows Encouraging Trial Results. Oct 25, 2011 499
Scottish Medicines Consortium Rules Against Breast Cancer Treatment Halaven(black triangle drug) (eribulin). Oct 10, 2011 1808
Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer. Oct 5, 2011 948
Drug combo prolongs progression-free survival time in breast cancer. Sep 26, 2011 293
Antibody-guided drug 'delays breast cancer progression in trials'. Sep 25, 2011 247
Roche to report new results for cancer treatments. Financial report Sep 19, 2011 151
Curis Announces Submission of New Drug Application by Collaborator Genentech for Vismodegib in Advanced Basal Cell Carcinoma. Sep 12, 2011 1989
Pfizera[euro](tm)s XALKORI receives US FDA approval for lung cancer treatment. Aug 29, 2011 347
U.S. Food And Drug Administration Approves Pfizer's XALKORI[R] (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer. Aug 26, 2011 3094
FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer. Aug 26, 2011 1101
FDA Grants Fast Track Designation to Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer Patients with Bone Metastases. Aug 23, 2011 954
Research and Markets: FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer. Aug 18, 2011 414
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer. Aug 17, 2011 1747
Plexxikon Announces FDA Approval of Zelboraf[TM] (vemurafenib) and Companion Diagnostic for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma. Aug 17, 2011 1722
QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer. Aug 5, 2011 1359
Qiagen completes second FDA submission for KRAS RGQ PCR Kit. Aug 5, 2011 211
Draft Nice Guidance on Advanced Breast Cancer Treatment, Halaven(R) Black Triangle Drug (Eribulin). Jul 19, 2011 1669
Drug combo can benefit more than 1 in 3 with hard-to-treat breast cancer. Jul 9, 2011 252
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE. Jul 6, 2011 1152
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE. Jun 30, 2011 1119
Zeltia begins studies of pancreatic cancer treatment drug. Jun 8, 2011 134
New drug shows promise in stopping prostate cancer spread to bone. Jun 8, 2011 270
Bio-Nucleonics Continues Production of Cancer Drug. Jun 7, 2011 407
New Breast Cancer Treatment Launched in UK. May 24, 2011 1505
Majority of Physicians Using Herceptin as Key Therapy for Gastric Cancer, But Satisfaction With Treatment Options Remains Low, According to Oncology Tracking Study by GfK HealthCare. Report May 17, 2011 594
Cancer Treatment Experts Detail Promising New Radiosurgical Techniques for Lung and Liver Cancer Patients. May 12, 2011 1225
Cancer Treatment Experts Detail Promising New Radiosurgical Techniques for Lung and Liver Cancer Patients. May 12, 2011 1236
Cytheris, Centre Leon Berard and ImmunID Announce Initiation of Clinical Trial to Evaluate Combination Regimen of IL-7 (CYT107) and XELODA[R] (capecitabine) in Treatment of Metastatic Breast Cancer. May 11, 2011 2366
FDA Approves New Treatment for Rare Type of Pancreatic Cancer. May 6, 2011 652
Food and Drug Administration Approves Abiraterone for Treatment of Men with Advanced Prostate Cancer. May 2, 2011 602
ZYTIGA(TM) (abiraterone acetate) Receives FDA Approval for Treatment of Metastatic Prostate Cancer After Priority Review. Apr 28, 2011 1717
FDA Approves Zytiga for Late-Stage Prostate Cancer. Apr 28, 2011 692
New Breast Cancer Treatment Launches in Sweden, Denmark and Finland. Apr 20, 2011 1482
AstraZeneca's orphan drug vandetanib receives FDA approval. Apr 7, 2011 267
FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer. Apr 6, 2011 1579
Pervasis Therapeutics Announces Positive Preclinical Study Data of Novel Cell Therapy for Treatment of Solid Tumors. Apr 5, 2011 1272
A case in which a combination of natural compounds was effective in metastatic breast cancer. Jurasunas, Serge Report Apr 1, 2011 2745
FDA clears Bristol-Myers' YERVOY for treatment of metastatic melanoma. Mar 28, 2011 197
Nordion Announces Phase III Clinical Trial to Evaluate TheraSphere(R) for Liver Metastases in Colorectal Cancer Patients. Mar 23, 2011 886
Dendreon Expands Launch of PROVENGE. Mar 10, 2011 1291
Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA. Feb 28, 2011 574
Bone drug may help prevent spread of early lung cancer. Feb 27, 2011 259
FDA grants Genentech hearing on Avastin's use for mBC. Feb 25, 2011 128
FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast Cancer in the United States. Feb 24, 2011 2259
Singapore HSA clears Eisai's Halaven for treatment of metastatic breast cancer. Disease/Disorder overview Feb 10, 2011 251
Emerging oral therapies for multiple sclerosis. Miller, Colleen E.; Umhauer, Margaret A. Report Feb 1, 2011 7701
Centocor Ortho Biotech seeks FDA nod for abiraterone acetate for metastatic advanced prostate cancer treatment. Dec 21, 2010 212
-FDA advisers support AstraZeneca's NDA for thyroid cancer drug. Dec 3, 2010 241
-FDA advisers support AstraZeneca's NDA for thyroid cancer drug. Dec 3, 2010 242
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET). Dec 2, 2010 1510
SUTENT Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET). Dec 2, 2010 1649
Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases. Dec 1, 2010 7951
Anti-angiogenic effect of siphonaxanthin from green alga, Codium fragile. Ganesan, Ponesakki; Matsubara, Kiminori; Ohkubo, Takeshi; Tanaka, Yukihisa; Noda, Kenji; Sugawara, T Dec 1, 2010 4459
Cancer drug developer Exelixis Inc (South San Francisco CA) said interim data from two mid-stage trials of an experimental drug showed promise in patients with a type of prostate cancer and ovarian cancer, sending its shares up 31% for the week. Nov 22, 2010 471
Eisai's Halaven Injection gains FDA nod for treatment of metastatic breast cancer. Nov 16, 2010 322
FDA Approves Eisai's Halaven[TM] (Eribulin Mesylate) Injection for Treatment of Metastatic Breast Cancer. Nov 15, 2010 1805
Gen-Probe Launches the ELUCIGENE(TM) KRAS.BRAF Kit to Detect Genetic Mutations That Help Determine Colorectal Cancer Treatment. Nov 8, 2010 970
Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE. Oct 27, 2010 991
Two Pivotal Vectibix Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology. Oct 4, 2010 3272
-AstraZeneca abandons registration plans for prostate cancer drug. Sep 27, 2010 159
AstraZeneca secures FDA approval for 500mg dose of FASLODEX Injection for metastatic breast cancer. Sep 13, 2010 169
Phase 2 Safety and Efficacy Data To Be Presented on Provectus' PV-10 at 7th International Melanoma Research Congress on November 4, 2010. Sep 13, 2010 552

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters